The age of psychedelics

Young, Allan H.

doi:10.1177/02698811211070065

Cited by 5 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psychedelics are prone to attract social narratives of hyperbole, which fuel patient expectations of transformational change. 43 This is unrealistic and comes with risks of its own. Lack of recovery in the presence of high expectations has the potential to worsen depression through disappointment.…”

Section: Adverse Effects and Risksmentioning

confidence: 99%

The development of psilocybin therapy for treatment-resistant depression: an update

Borissova

Rucker

2023

BJPsych Bull

View full text Add to dashboard Cite

Summary Psilocybin is a classic psychedelic drug that has attracted increasing research interest over the past 10 years as a possible treatment for mood, anxiety and related conditions. Initial phase 2 clinical trials of psilocybin given alongside psychological support for major depression and treatment-resistant depression (TRD) demonstrated encouraging signs of basic safety, further confirmed by a large study in groups of healthy volunteers. The first international multi-centre randomised controlled trial was published in 2022, with signs of efficacy for the 25 mg dose condition in people with TRD when compared with an active placebo. Phase 3 trials in TRD are scheduled to start in 2023. Early evidence suggests that single doses of psilocybin given with psychological support induce rapid improvement in depressive symptoms that endure for some weeks. We therefore provide a timely update to psychiatrists on what psilocybin therapy is, what it is not, and the current state of the evidence-base.

show abstract

Section: Adverse Effects and Risksmentioning

confidence: 99%

The development of psilocybin therapy for treatment-resistant depression: an update

Borissova

Rucker

2023

BJPsych Bull

View full text Add to dashboard Cite

show abstract

“…The 21st century brought a renewed focus in academia on entheogens and psychedelics as a therapeutic intervention (Young, 2022). Researchers at The Center for Psychedelic and Consciousness Research at Johns Hopkins University were the first to obtain regulatory approval from the United States government to re-establish research in the therapeutic use of psychedelics (Lewis, 2020).…”

Section: Psychedelic Clinical Researchmentioning

confidence: 99%

“…This shift would move researchers away from foundational cause-andeffect and reductionistic-oriented assumptions thereby avoiding scientific bias resulting from positivist scientific theory that blinds the researcher to emergent variables so obvious to entheogenic ritual practitioners and clinical psychedelic experiences. Critical realists and pragmatic research philosophy are both well suited for examining context (Carhart-Harris et al, 2022;Young, 2022) because the researcher is free to choose the methods, techniques, and procedures that best meet the needs and purpose of the research question rather than subscribing to only one method such as clinical trials. It provides a platform for utilizing mixed methods research to access varied forms of data collection and analysis providing a more comprehensive examination of what could be occurring in any given phenomenon.…”

Section: Considerations For Research Philosophymentioning

confidence: 99%

JSE 36:4 Winter 2022 Full Issue

Laythe

2023

JSE

View full text Add to dashboard Cite

show abstract

“…As we head into the (Northern Hemisphere) spring, the Journal publishes another set of papers which illustrate the robust health of the science of psychopharmacology. Once again, papers mostly focus on psychedelic drugs and related topics reflecting the zeitgeist (Young, 2022). de Wit et al (2022) explore translational challenges and opportunities between clinical research and laboratory settings.…”

mentioning

confidence: 99%